Research Article 
Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer‘s disease
Michael W. Weiner, Carl Sadowsky, Judith Saxton, Robert K. Hofbauer, Stephen M. Graham, ung Yun Yu, Shaoyi Li, Hai-An Hsu, Joyce Suhy, Moshe Fridman and James L. Perhach
Alzheimer`s & Dementia, 2011, 7(4), 425-435. DOI: 10.1016/j.jalz.2010.09.003
Abstract
Background This study was designed to assess changes in brain volume and cognitive abilities in memantine-treated patients with Alzheimer‘s disease (AD) by using an exploratory, single-arm, delayed-start design. Methods Cholinesterase inhibitor-treated patients with AD (N = 47; Mini-Mental State Examination score range: 15–23) were enrolled in an observational lead-in period (weeks: 1–24), followed by an open-label period of add-on memantine treatment (weeks: 25–48). The patients underwent magnetic resonance imaging at weeks 0 (baseline), 24 (immediately before memantine initiation), and 48 (endpoint), and a battery of neuropsychological tests at weeks 0, 24, 28, 36, and 48. The primary outcome measure was the annualized rate of change (%) in total brain volume (TBV) between the two study periods. Data were analyzed using paired t-tests. Results There were no statistically significant differences in the rates of change in TBV, ventricular volume, or left hippocampal volume between the study periods; however, the memantine treatment period was associated with a significantly slower right hippocampal atrophy (−5.5% ± 12.0% vs −10.8% ± 7.2%; P = .038). Memantine treatment was also associated with superior performances on the Boston Naming Test (P = .034) and the Trail Making Test, Part B (P = .001), but also with a higher number of errors (i.e., repetitions and intrusions) on the California Verbal Learning Test. Memantine was found to be safe and well tolerated. Conclusions In this study, no difference in the rates of TBV change between the two periods was observed; however, memantine treatment was found to be associated with slowing of right hippocampal atrophy, and with improvement on one test of executive functioning as well as a test of confrontation naming ability. Trials using structural magnetic resonance imaging and a delayed-start design may be a feasible option for the assessment of treatments for AD.
ASCI-ID: 285-152
Similar Articles
A European perspective on population studies of dementia
Alzheimer`s & Dementia, 2011, 7(1), 3-9. DOI: 10.1016/j.jalz.2010.12.003
Operationalizing diagnostic criteria for Alzheimer‘s disease and other age-related cognitive impairment–Part 2Alzheimer`s & Dementia, 2011, 7(1), 35-52. DOI: 10.1016/j.jalz.2010.12.002
Sources of variability in estimates of the prevalence of Alzheimer‘s disease in the United StatesAlzheimer`s & Dementia, 2011, 7(1), 74-79. DOI: 10.1016/j.jalz.2010.11.006
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloidAlzheimer`s & Dementia, 2011, 7(2), 133-141. DOI: 10.1016/j.jalz.2010.08.230
Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer`s & Dementia, 2011, 7(3), 257-262. DOI: 10.1016/j.jalz.2011.03.004
The Alzheimer‘s Association external quality control program for cerebrospinal fluid biomarkersAlzheimer`s & Dementia, 2011, 7(4), 386-395. DOI: 10.1016/j.jalz.2011.05.2243
Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer‘s disease study cohorts from phase 3 trials of semagacestat and solanezumabAlzheimer`s & Dementia, 2011, 7(4), 396-401. DOI: 10.1016/j.jalz.2011.05.2353
Extended results of the Alzheimer‘s disease anti-inflammatory prevention trialAlzheimer`s & Dementia, 2011, 7(4), 402-411. DOI: 10.1016/j.jalz.2010.12.014
Intracranial atherosclerosis as a contributing factor to Alzheimer‘s disease dementiaAlzheimer`s & Dementia, 2011, 7(4), 436-444. DOI: 10.1016/j.jalz.2010.08.228
Transcranial Doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2011, 7(4), 445-455. DOI: 10.1016/j.jalz.2010.09.002
The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ɛ3/ɛ3 genotypeAlzheimer`s & Dementia, 2011, 7(4), 456-465. DOI: 10.1016/j.jalz.2010.11.012
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2011, 7(4), 474-485. DOI: 10.1016/j.jalz.2011.04.007
Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer‘s disease patientsAlzheimer`s & Dementia, 2011, 7(5), 493-500. DOI: 10.1016/j.jalz.2011.01.004
Frequency of Alzheimer‘s disease pathology at autopsy in patients with clinical normal pressure hydrocephalusAlzheimer`s & Dementia, 2011, 7(5), 509-513. DOI: 10.1016/j.jalz.2010.12.008
Long-term progression of Alzheimer‘s disease in patients under antidementia drugsAlzheimer`s & Dementia, 2011, 7(6), 579-592. DOI: 10.1016/j.jalz.2011.02.009
The measurement of everyday cognition: Development and validation of a short form of the Everyday Cognition scalesAlzheimer`s & Dementia, 2011, 7(6), 593-601. DOI: 10.1016/j.jalz.2011.02.007
Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer‘s disease trialsAlzheimer`s & Dementia, 2011, 7(6), 602-610. DOI: 10.1016/j.jalz.2011.01.005
An economic evaluation of early assessment for Alzheimer‘s disease in the United KingdomAlzheimer`s & Dementia, 2012, 8(1), 22-30. DOI: 10.1016/j.jalz.2010.07.001
Modeling Alzheimer‘s disease progression using the disease system analysis approachAlzheimer`s & Dementia, 2012, 8(1), 39-50. DOI: 10.1016/j.jalz.2010.12.012
Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's diseaseAlzheimer`s & Dementia, 2012, 8(1), 51-59. DOI: 10.1016/j.jalz.2011.06.003
Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization InitiativeAlzheimer`s & Dementia, 2012, 8(1), 65-73. DOI: 10.1016/j.jalz.2011.07.004
[123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodiesAlzheimer`s & Dementia, 2012, 8(1), 74-83. DOI: 10.1016/j.jalz.2011.08.003
An investigation of PreMCI: Subtypes and longitudinal outcomesAlzheimer`s & Dementia, 2012, 8(3), 172-179. DOI: 10.1016/j.jalz.2011.03.002
Serum antibodies to periodontal pathogens are a risk factor for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(3), 196-203. DOI: 10.1016/j.jalz.2011.04.006
Cognitive and structural magnetic resonance imaging features of Lewy body dementia and Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(3), 211-218. DOI: 10.1016/j.jalz.2011.04.008
Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(3), 219-226. DOI: 10.1016/j.jalz.2011.03.012
Alzheimer‘s disease: Pathogenesis and preventionAlzheimer`s & Dementia, 2012, 8(3), 227-233. DOI: 10.1016/j.jalz.2012.01.011
The epidemiology of Alzheimer‘s disease: Laying the foundation for drug design, conduct, and analysis of clinical trialsAlzheimer`s & Dementia, 2012, 8(3), 237-242. DOI: 10.1016/j.jalz.2011.12.005
Safety and biomarker effects of solanezumab in patients with Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(4), 261-271. DOI: 10.1016/j.jalz.2011.09.224
Leptin and dementia over 32 years–The Prospective Population Study of WomenAlzheimer`s & Dementia, 2012, 8(4), 272-277. DOI: 10.1016/j.jalz.2011.05.2411
Gaining precision on the Alzheimer‘s Disease Assessment Scale-cognitive: A comparison of item response theory-based scores and total scoresAlzheimer`s & Dementia, 2012, 8(4), 288-294. DOI: 10.1016/j.jalz.2011.05.2409
Effect of human cerebrospinal fluid sampling frequency on amyloid-β levelsAlzheimer`s & Dementia, 2012, 8(4), 295-303. DOI: 10.1016/j.jalz.2011.05.900
Worldwide Alzheimer‘s Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2012, 8(4), 337-342. DOI: 10.1016/j.jalz.2012.04.007
Some evolutionary perspectives on Alzheimer‘s disease pathogenesis and pathologyAlzheimer`s & Dementia, 2012, 8(4), 343-351. DOI: 10.1016/j.jalz.2011.05.2408
Cardiovascular fitness is associated with altered cortical glucose metabolism during working memory in ɛ4 carriersAlzheimer`s & Dementia, 2012, 8(4), 352-356. DOI: 10.1016/j.jalz.2011.04.010
Common Alzheimer‘s Disease Research Ontology: National Institute on Aging and Alzheimer‘s Association Collaborative ProjectAlzheimer`s & Dementia, 2012, 8(4), 372-375. DOI: 10.1016/j.jalz.2012.05.2115
A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in agingAlzheimer`s & Dementia, 2012, 8(5), 381-388. DOI: 10.1016/j.jalz.2011.10.005
Amyloid imaging in dementias with atypical presentationAlzheimer`s & Dementia, 2012, 8(5), 389-398. DOI: 10.1016/j.jalz.2011.07.003
Comparing new templates and atlas-based segmentations in the volumetric analysis of brain magnetic resonance images for diagnosing Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(5), 399-406. DOI: 10.1016/j.jalz.2011.07.002
Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studiesAlzheimer`s & Dementia, 2012, 8(5), 407-416. DOI: 10.1016/j.jalz.2011.05.2413
Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound BAlzheimer`s & Dementia, 2012, 8(6), 496-501. DOI: mailto:[email protected]
Greater regional brain atrophy rate in healthy elderly subjects with a history of cigarette smokingAlzheimer`s & Dementia, 2012, 8(6), 513-519. DOI: 10.1016/j.jalz.2011.10.006
Differential prediction of vascular dementia and Alzheimer‘s disease in nondemented older adults within 5 years of initial testingAlzheimer`s & Dementia, 2012, 8(6), 528-535. DOI: 10.1016/j.jalz.2011.09.233
A new informant-based questionnaire for instrumental activities of daily living in dementiaAlzheimer`s & Dementia, 2012, 8(6), 536-543. DOI: 10.1016/j.jalz.2011.08.006
Comparison of International Working Group criteria and National Institute on Aging–Alzheimer‘s Association criteria for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(6), 560-563. DOI: 10.1016/j.jalz.2011.10.008
Association of environmental tobacco smoke with dementia and Alzheimer‘s disease among never smokersAlzheimer`s & Dementia, 2012, 8(6), 590-595. DOI: 10.1016/j.jalz.2011.09.231
The worldwide economic impact of dementia 2010Alzheimer`s & Dementia, 2013, 9(1), 1-11. DOI: 10.1016/j.jalz.2012.11.006
Apolipoprotein E genotype, dementia, and mortality in the oldest old: The 90+ StudyAlzheimer`s & Dementia, 2013, 9(1), 12-18. DOI: 10.1016/j.jalz.2011.12.004
Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer‘s disease and related disordersAlzheimer`s & Dementia, 2013, 9(1), 30-38. DOI: 10.1016/j.jalz.2012.11.002
The economics of mild cognitive impairmentAlzheimer`s & Dementia, 2013, 9(1), 58-62. DOI: 10.1016/j.jalz.2012.05.2117
Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on AgingAlzheimer`s & Dementia, 2013, 9(2), 113-122. DOI: 10.1016/j.jalz.2011.09.223
Intracerebral propagation of Alzheimer‘s disease: Strengthening evidence of a herpes simplex virus etiologyAlzheimer`s & Dementia, 2013, 9(2), 169-175. DOI: 10.1016/j.jalz.2012.07.005
Phenotypic regional functional imaging patterns during memory encoding in mild cognitive impairment and Alzheimer's diseaseAlzheimer`s & Dementia, 2013, 9(3), 284-294. DOI: 10.1016/j.jalz.2011.12.006
Effectiveness of antidementia drugs in delaying Alzheimer's disease progressionAlzheimer`s & Dementia, 2013, 9(3), 338-345. DOI: 10.1016/j.jalz.2012.01.002
Risk disclosure and preclinical Alzheimer‘s disease clinical trial enrollmentAlzheimer`s & Dementia, 2013, 9(3), 356-359. DOI: 10.1016/j.jalz.2012.03.001
β-Site amyloid precursor protein–cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tauAlzheimer`s & Dementia, 2013, 9(4), 386-391. DOI: 10.1016/j.jalz.2012.01.015
Costs of care in a mild-to-moderate Alzheimer clinical trial sample: Key resources and their determinantsAlzheimer`s & Dementia, 2011, 7(4), 466-473. DOI: 10.1016/j.jalz.2010.06.002
Gaining precision on the Alzheimer‘s Disease Assessment Scale-cognitive: A comparison of item response theory-based scores and total scoresAlzheimer`s & Dementia, 2012, 8(4), 288-294. DOI: 10.1016/j.jalz.2011.05.2409
Effect of human cerebrospinal fluid sampling frequency on amyloid-β levelsAlzheimer`s & Dementia, 2012, 8(4), 295-303. DOI: 10.1016/j.jalz.2011.05.900
Risk disclosure and preclinical Alzheimer‘s disease clinical trial enrollmentAlzheimer`s & Dementia, 2013, 9(3), 356-359. DOI: 10.1016/j.jalz.2012.03.001
Update on the Magnetic Resonance Imaging core of the Alzheimer’s Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2010, 6(3), 212-220. DOI: 10.1016/j.jalz.2010.03.004
Addressing population aging and Alzheimer’s disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer’s Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2010, 6(3), 291-296. DOI: 10.1016/j.jalz.2010.03.009
Cerebral blood flow in ischemic vascular dementia and Alzheimer's disease, measured by arterial spin-labeling magnetic resonance imagingAlzheimer`s & Dementia, 2009, 5(6), 454-462. DOI: 10.1016/j.jalz.2009.04.1233
Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer‘s disease study cohorts from phase 3 trials of semagacestat and solanezumabAlzheimer`s & Dementia, 2011, 7(4), 396-401. DOI: 10.1016/j.jalz.2011.05.2353
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2011, 7(4), 474-485. DOI: 10.1016/j.jalz.2011.04.007
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2011, 7(4), 474-485. DOI: 10.1016/j.jalz.2011.04.007
Comparing new templates and atlas-based segmentations in the volumetric analysis of brain magnetic resonance images for diagnosing Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(5), 399-406. DOI: 10.1016/j.jalz.2011.07.002
Global gray matter changes in posterior cortical atrophy: A serial imaging studyAlzheimer`s & Dementia, 2012, 8(6), 502-512. DOI: 10.1016/j.jalz.2011.09.225
Vascular disease and dementias: Paradigm shifts to drive research in new directionsAlzheimer`s & Dementia, 2013, 9(1), 76-92. DOI: 10.1016/j.jalz.2012.02.007
Homocysteine, progression of ventricular enlargement, and cognitive decline: The Second Manifestations of ARTerial disease–Magnetic Resonance studyAlzheimer`s & Dementia, 2013, 9(3), 302-309. DOI: 10.1016/j.jalz.2011.11.008
Effects of Food and Drug Administration-approved medications for Alzheimer‘s disease on clinical progressionAlzheimer`s & Dementia, 2012, 8(3), 180-187. DOI: 10.1016/j.jalz.2011.02.011
Outcome over seven years of healthy adults with and without subjective cognitive impairmentAlzheimer`s & Dementia, 2010, 6(1), 11-24. DOI: 10.1016/j.jalz.2009.10.002
Prevalence of mild cognitive impairment subtypes in patients attending a memory outpatient clinic—comparison of two modes of mild cognitive impairment classification. Results of the Vienna Conversion to Dementia StudyAlzheimer`s & Dementia, 2013, 9(4), 366-376. DOI: 10.1016/j.jalz.2011.12.009